IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinase-like orphan receptor 1 (ROR1) molecules for their therapeutic potential against sarcomas. Here, we report that IGF1R (15/15) and ROR1 (11/15) were highly expressed in sarcoma cell lines including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma. IGF1R and ROR1 CAR T cells derived from eight healthy donors using the Sleeping Beauty (SB) transposon system were cytotoxic against sarcoma cells and produced high levels of IFN-γ, TNF-α and IL-13 in an antigen-specific manner. IGF1R and ROR1 CAR T cells generated from three sarcoma patients released significant amounts of IFN-γ in response to sarcoma stimulation. The adoptive transfer of IGF1R and ROR1 CAR T cells derived from a sarcoma patient significantly reduced tumor growth in pre-established, systemically disseminated and localized osteosarcoma xenograft models in NSG mice. Infusion of IGF1R and ROR1 CAR T cells also prolonged animal survival in a localized sarcoma model using NOD/scid mice. Our data indicate that both IGF1R and ROR1 can be effectively targeted by SB modified CAR T cells and that such CAR T cells may be useful in the treatment of high risk sarcoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The preclinical study conducted by Huang et al. demonstrated that IGF1R and ROR1 CAR-T cells exhibited significantly tumor growth inhibition and survival extension on sarcoma [127].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 4×
“Recent Phase I clinical trials with CD19-targeted, 2 generation of chimeric antigen receptor (CAR) T cells containing 4-1BB signaling domain have shown a complete remission (CR) rate of>86% in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [3].”
BackgroundInfluentialChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632 · cited 1×
“In sarcomas, ACT with NY-ESO-1 TCR has demonstrated objective clinical responses in four of six patients with synovial cell sarcoma [8].”
BackgroundPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116 · cited 3×
“Therefore, successful targeting IGF1R has a broad impact on cancer treatment [17, 42, 43].”
BackgroundAhmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703 · cited 1×
“First, they directly and specifically kill IGF1R cancer cells even at a low level of surface expression as CD8 CTLs are capable of responding to a single antigen molecule [48].”
BackgroundAntibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Cited by
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
“An adoptive transfer of IGFR1-CAR and ROR1-CAR T cells derived from a sarcoma patient significantly suppressed tumor growth in both localized and disseminated sarcoma xenograft models [153].”
BackgroundEwing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The preclinical study conducted by Huang et al. demonstrated that IGF1R and ROR1 CAR-T cells exhibited significantly tumor growth inhibition and survival extension on sarcoma [127].”
MethodCAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.128 · Cited by 220
Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind, M. F., Wagner, L. M., & Cripe, T. P. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27227 · Cited by 173
The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention
Menck, K., Heinrichs, S., Baden, C., & Bleckmann, A. (2021) · Cells · doi:10.3390/cells10010142 · Cited by 137
“, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma) [191].”
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 121
“Other preclinical models of solid tumors utilizing CAR-T directed against IL11-R-a and HER2, or CAR-T against IGF1-R and tyrosine-kinase-like orphan receptor 1 showed suppressed tumor growth and prolonged animal survival [34, 68].”
BackgroundPreclinical and clinical advances in transposon-based gene therapy
Tipanee, J., Chai, Y. C., VandenDriessche, T., & Chuah, M. K. (2017) · Bioscience Reports · doi:10.1042/bsr20160614 · Cited by 89
Role of immunotherapy in Ewing sarcoma
Morales, E., Olson, M., Cardenas, F. I., Dahiya, S., Luetkens, T., & Atanackovic, D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000653 · Cited by 98
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
Soltantoyeh, T., Akbari, B., Karimi, A., Chalbatani, G. M., Ghahri-Saremi, N., Hadjati, J., Hamblin, M. R., & Mirzaei, H. R. (2021) · Cells · doi:10.3390/cells10061450 · Cited by 93
“Chemotactic molecules CXCR3 Melanoma tumor cells No IGF-1R Melanoma tumor cells Yes [160] CXCR4 Melanoma tumor cells No CCR9 Melanoma tumor cells No -”
BackgroundZhang, Y., Li, Y., Cao, W., Wang, F., Xie, X., Li, Y., Wang, X., Guo, R., Jiang, Z., & Guo, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799206 · Cited by 94
“(B) Summarization of high IGF1R/CD1A/CCR9/CXCR4-expressing subpopulations in various tissues and organs.”
BackgroundInfluentialRecent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 101
“reported that IGF-1R and tyrosine kinase-like orphan receptor 1 (ROR1) were strongly expressed in Ewing sarcoma, osteosarcoma, ARMS, ERMS, and fibrosarcoma cell lines [92].”
BackgroundCancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H. Z., Jeandet, P., Mirzaei, H., & Mirzaei, H. R. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.015 · Cited by 90
Hettmer, S., Linardic, C. M., Kelsey, A. M., Rudzinski, E. R., Vokuhl, C., Selfe, J., Ruhen, O., Shern, J. F., Khan, J. I., Kovach, A. R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.036 · Cited by 88
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101934 · Cited by 78
“A recent study evaluated CAR-T cells targeting IGF-1R or ROR1 in sarcomas [54].”
BackgroundTumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 75
Nguyen, T., & Barr, F. G. (2018) · Molecules · doi:10.3390/molecules23112798 · Cited by 74
“In addition, IGFR1-specific CAR T cells were recently developed, and initial results indicated that they suppress growth of several sarcoma categories expressing this receptor in both cell line and xenograft systems [164].”
BackgroundBone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 63
“Diverse CAR T-cells have been developed based on this concept: CAR T-targeting B7-H3 (Majzner et al., 2019), IFGR-1 and ROR1 (Huang et al., 2015), IL-11 (Huang et al., 2012), folate receptor (Lu et al., 2019), NKG2D/4-1BB/CD3z domains (Fernández et al., 2017), and CD166/4-1BB (Wang et al., 2019).”
MethodTreating osteosarcoma with CAR T cells
Köksal, H., Müller, E., Inderberg, E. M., Bruland, Ø. S., & Wälchli, S. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12741 · Cited by 58
“Recently, Huang and colleagues [51] tested both IGFR1 CAR and ROR1 CAR constructs against sarcoma cell lines and found that redirected T cells were indeed able to kill such cells in vitro.”
BackgroundPotential approaches to the treatment of Ewing's sarcoma
Yu, H., Ge, Y., Guo, L., & Huang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.12566 · Cited by 55
“IGF1R and ROR1 CAR T cells showed cytotoxic responses against sarcoma cells including ES [142].”
BackgroundImmunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
“OS IGF1R and ROR1 CAR T cells -IGF1R and ROR1 CAR T cells derived suppressed sarcoma growth in vivo No data -both CAR T cells extended overall survival compared to the untreated group -produced high amounts of IL13 Th2 cytokine but not IL4 and IL10 in vitro [80]”
BackgroundProgress and Opportunities for Immune Therapeutics in Osteosarcoma
Lettieri, C. K., Appel, N., Labban, N., Lussier, D. M., Blattman, J. N., & Hingorani, P. (2016) · Immunotherapy · doi:10.2217/imt-2016-0048 · Cited by 54
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR
Borgatti, A., Koopmeiners, J. S., Sarver, A. L., Winter, A. L., Stuebner, K., Todhunter, D., Rizzardi, A. E., Henriksen, J. C., Schmechel, S., Forster, C. L., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0637 · Cited by 54
Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00221-4 · Cited by 51
“of normal tissue distribution [10], importantly, our data shows”
BackgroundResultInfluentialProtein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis
Luo, W., Xu, C., Ayello, J. S., Cruz, F. S. D., Rosenblum, J., Lessnick, S. L., & Cairo, M. S. (2017) · Oncogene · doi:10.1038/onc.2017.378 · Cited by 57
Self-citationCD44v6 as innovative sarcoma target for CAR-redirected CIK cells
Leuci, V., Casucci, M., Grignani, G., Rotolo, R., Rossotti, U., Vigna, E., Gammaitoni, L., Mesiano, G., Fiorino, E., Donini, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423167 · Cited by 48
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Ali, A. I., Oliver, A. J., Samiei, T., Chan, J. D., Kershaw, M. H., & Slaney, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00056 · Cited by 50
“IGF1R-CAR cells have demonstrated efficacy in murine models of sarcoma xenograft (65) and could be potentially useful in the treatment of PDAC.”
BackgroundPotratz, J. C., Tillmanns, A. E., Berning, P., Korsching, E., Schaefer, C., Lechtape, B., Schleithoff, C., Unland, R., Schäfer, K.-L., Müller‐Tidow, C., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.009 · Cited by 49
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma
Englisch, A., Altvater, B., Kailayangiri, S., Hartmann, W., & Rössig, C. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28313 · Cited by 49
Ghaderi, A., Daneshmanesh, A. H., Moshfegh, A., Kokhaei, P., Vågberg, J., Schultz, J., Olin, T., Harrysson, S., Smedby, K. E. E., Drakos, E., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8060170 · Cited by 44
“In recent years, ROR1 has emerged as a molecule of substantial interest for the development of targeted therapy including mAbs [15], chimeric antigen receptor T-cells (CAR-T) [39,40], bi-specific T-cell engager (BiTE) [41] and SMIs targeting the cytoplasmic tyrosine kinase domain (TKI) [29,42] as well as the extracell…”
BackgroundCancer diagnostics: The journey from histomorphology to molecular profiling
Ahmed, A. A., & Abedalthagafi, M. (2016) · Oncotarget · doi:10.18632/oncotarget.11061 · Cited by 47
Talbot, L. J., Chabot, A., Funk, A., Nguyen, P., Wagner, J., Ross, A. B., Tillman, H. S., Davidoff, A. M., Gottschalk, S. M., & DeRenzo, C. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691741 · Cited by 44
“For primary tumor modeling, these have included periosteal injection (26, 32), intratibial injection (11, 33–35), an intraperitoneal loco-regional model (13, 36), and subcutaneous injection (34, 37–41).”
BackgroundChen, P.-C., Kuo, Y., Chuong, C., & Huang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.625943 · Cited by 40
The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
Tzanakakis, G. N., Giatagana, E.-M., Berdiaki, A., Spyridaki, I., Hida, K., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2021) · Cancers · doi:10.3390/cancers13102478 · Cited by 41
Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02838-3 · Cited by 40
“The corresponding CAR T cells showed effective in vitro RMS cell lysis, but have not been tested in vivo [25].”
BackgroundCurrent status and future challenges of CAR-T cell therapy for osteosarcoma
Li, S., Zhang, H., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290762 · Cited by 39
“In a xenograft mouse model, CAR-T therapy targeting IGF1R inhibited tumor growth and prolonged survival (32).”
BackgroundPellegrino, M., Secli, V., D’Amico, S., Petrilli, L. L., Caforio, M., Folgiero, V., Tumino, N., Vacca, P., Vinci, M., Fruci, D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356321 · Cited by 34
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 38
Immunotherapy and Biomarkers in Sarcoma
Dajsakdipon, T., Siripoon, T., Ngamphaiboon, N., Ativitavas, T., & Dejthevaporn, T. S. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00944-6 · Cited by 31
CAR T targets and microenvironmental barriers of osteosarcoma
Zhu, J., Simayi, N., Wan, R., & Huang, W. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.010 · Cited by 33
Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies
Folkert, I. W., Devalaraja, S., Linette, G. P., WEBER, K. L., & Haldar, M. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3852 · Cited by 31
“The type 1 insulin-like growth factor receptor (IGF1R) and the tyrosine kinase-like orphan receptor 1 (ROR1) have also been explored as potential CAR-T targets by Huang and colleagues.((63)) Bothmolecules are highly expressed in sarcoma cell lines, including OS and ES.”
BackgroundProspects for NK Cell Therapy of Sarcoma
Lachota, M., Vincenti, M., Winiarska, M., Boye, K., Zagożdżon, R., & Malmberg, K. (2020) · Cancers · doi:10.3390/cancers12123719 · Cited by 29
“It is widely expressed across different sarcoma subtypes, and in vitro studies have proven anti-ROR1 CAR NK cells to effectively induce U2OS cell lysis, accompanied by increased IFN-γ secretion [238,239].”
BackgroundAnti-ROR1 CAR-T cells: Architecture and performance
Osorio-Rodríguez, D. A., Camacho, B., & Ramirez-Segura, C. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1121020 · Cited by 27
A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
Lin, Z., Wu, Z., & Luo, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707211 · Cited by 27
“The binding of ligand to the IGF1Ra subunit leads to the autophosphorylation of b subunit and the recruitment of adaptor proteins, ultimately resulting in the activation of signaling cascades that in turn contributes to proliferation, survival, transformation, metastasis, and angiogenesis (19, 29, 30).”
BackgroundInfluentialCurrent Landscape of Immunotherapy for Advanced Sarcoma
Albarrán, V., Villamayor, M. L., Pozas, J., Chamorro, J., Rosero, D. I., Román, M. S., Guerrero, P., de Aguado, P. P., Calvo, J. C., de Quevedo, C. G., et al. (2023) · Cancers · doi:10.3390/cancers15082287 · Cited by 29
“Preclinical studies have also suggested a promising activity of CAR T cells targeting the type I insulin-like growth factor receptor (IGF1R) and the tyrosine–kinase-like orphan receptor 1 (ROR1), which are highly expressed in sarcoma cell lines [178].”
BackgroundLi, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 27
“[50,51] These data supported ROR1-CAR-T cells as a potential treatment for sarcoma.”
MethodTherapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells
Kamrani, A., Mehdizadeh, A., Ahmadi, M., Maleki, L. A., & Yousefi, M. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1602608 · Cited by 25
“kines predominantly release against sarcomas in vitro [72].”
BackgroundTargeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 27
“CAR-T targeting GPR64, ROR1, and IGF1R, which are highly expressed in EwS [137,208], leads to a selective killing of EwS in vivo [209].”
BackgroundROR1 and ROR2—novel targets for neuroblastoma
Dave, H., Butcher, D. O., Anver, M. R., & Bollard, C. M. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1646365 · Cited by 27
CAR T-Cell Therapy in Children with Solid Tumors
Kulczycka, M., Derlatka, K., Tasior, J., Lejman, M., & Zawitkowska, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062326 · Cited by 27
Natural Killer Cell Immunotherapy for Osteosarcoma
Tullius, B. P., Setty, B. A., & Lee, D. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_12 · Cited by 22
Terry, R. L., Meyran, D., Fleuren, E. D. G., Mayoh, C., Zhu, J. J., Omer, N., Ziegler, D. S., Haber, M., Darcy, P. K., Trapani, J. A., et al. (2021) · Cancers · doi:10.3390/cancers13184704 · Cited by 24
“ROR1 Osteosarcoma Cytotoxicity against osteosarcoma cell line SaOS2 Produced high levels of Th1 cytokines (IFN-γ and TNF-α) Delayed tumor growth in mice bearing SaOS2 [47]”
BackgroundOverhauling CAR T Cells to Improve Efficacy, Safety and Cost
Chicaybam, L., Bonamino, M., Invitti, A. L., Rozenchan, P. B., Vieira, I. D. L., & Strauss, B. E. (2020) · Cancers · doi:10.3390/cancers12092360 · Cited by 21
“Even so, transposon mediated gene transfer of CARs targeting mesothelin [129], CD56 [130], EGFR (epidermal growth factor receptor) [131], CD116 [132], IGF1R (insulin-like growth factor 1 receptor) and ROR1 (receptor tyrosine kinase like orphan receptor 1) [133] and HERV-K (human endogenous retrovirus-K) [134] have bee…”
BackgroundTellez, C. M., Leyfman, Y., D’Angelo, S. P., Wilky, B. A., & Dufresne, A. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.03.004 · Cited by 22
Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
Lin, Z., Wu, Z., & Luo, W. (2021) · Cancers · doi:10.3390/cancers13174469 · Cited by 21
“They further found that ROR1targeted CAR-T cells remarkedly suppressed sarcoma growth in pre-established localized and disseminated sarcoma xenograft models associated with prolonged survival [25].”
BackgroundInfluentialFunctional and clinical significance of ROR1 in lung adenocarcinoma
Schiavone, G., Epistolio, S., Martin, V., Molinari, F., Barizzi, J., Mazzucchelli, L., Frattini, M., & Wannesson, L. (2020) · BMC Cancer · doi:10.1186/s12885-020-07587-6 · Cited by 23
IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis
Mytilinaiou, M. G., Nikitovic, D., Berdiaki, A., Papoutsidakis, A., Papachristou, D. J., Tsatsakis, A. M., & Tzanakakis, G. N. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.035 · Cited by 19
“IGF-I is implicated in the regulation of apoptosis, angiogenesis and metastasis and it is able to promote cancer progression through its receptor IGF-IR [12,61], which is highly expressed on the cell surface of HT1080 cells [62].”
Precision medicine approaches for the management of Ewing sarcoma: current perspectives
Rizk, V. T., Walko, C. M., & Brohl, A. S. (2019) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s170612 · Cited by 17
“Thus far, there has been success in ES mouse models leading to a prolonged overall survival, but results have been limited to preclinical studies.(48)”
BackgroundJin, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00613 · Cited by 19
Lin, S.-L., Lin, C., Lee, W., Teng, C., Shyu, W., & Jeng, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911781 · Cited by 18
“For example, the precise targeting of IGF-1R is feasible through the bioengineering of patient-derived chimeric antigen receptor (CAR)-T cells in sarcomas [23].”
BackgroundGhaderi, A., Okhovat, M. A., Lehto, J., Petris, L. D., Doulabi, E. M., Kokhaei, P., Zhong, W., Rassidakis, G. Z., Drakos, E., Moshfegh, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041148 · Cited by 16
“ROR1 has been described as an oncogenic molecule of interest for the development of targeted therapy for antibody-drug conjugates [67], chimeric antigen receptor T-cells (CAR-T) [68,69], mAbs [27], and bi-specific T-cell engager (BiTE) [70], as well as SMIs targeting the intracellular [20,56] or extracellular parts of…”
BackgroundHeterogeneous Profile of ROR1 Protein Expression across Tumor Types
Raso, M. G., Barrientos-Toro, E., Evans, K. W., Rizvi, Y. Q., Lazcano, R., Akçakanat, A., Sini, P., Trapani, F., Madlener, E. J., Waldmeier, L., et al. (2024) · Cancers · doi:10.3390/cancers16101874 · Cited by 15
“ROR1 expression data in high-risk sarcoma, including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma, have been published [25,26], but none was found for liposarcoma.”
BackgroundTargeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 20
A Review of T-Cell Related Therapy for Osteosarcoma
Yoshida, K., Okamoto, M., Aoki, K., Takahashi, J., & Saito, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144877 · Cited by 16
“As well as the HER2 CAR T-cells, Disialoganglioside (GD2) [52], Interleukin 11 receptor alpha subunit (IL-11RA) [53], Insulin-like growth factor 1 receptor (IGF-1R) with receptor tyrosine kinase orphan-like receptor 1 (ROR1) [54], and B7-H3 [55] are reported as good targets in vitro or in vivo using mouse studies.”
BackgroundStrategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
Hattinger, C. M., Salaroglio, I. C., Fantoni, L., Godel, M., Casotti, C., Kopecka, J., Scotlandi, K., Ibrahim, T., Riganti, C., & Serra, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010799 · Cited by 16
“The combined use of different ICPs, alone or combined with radiotherapy [106], or of ICPs plus L-arginine, an essential aminoacid for T lymphocytes, increased CD8 + T-lymphocyte infiltration and tumoricidal activity, as demonstrated by their increased release of IFN-γ , granzyme B and perforin [107].”
InfluentialGenetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s
DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12
Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?
Paudel, A., Chattopadhyay, P., Rose, B., Watson, A., D’Amato, G. Z., Trent, J. C., Bialick, S., & Jonczak, E. (2025) · Cancers · doi:10.3390/cancers17050889 · Cited by 13
“Notable SAAs under investigation in STSs with encouraging results include human epidermal growth factor receptor 2 (HER2) [108,109], disialogan-glioside (GD2) [110,111], receptor tyrosine kinase-like orphan receptor 1 (ROR1) [112], and CD44v6 [113].”
Wang, H., & Pan, W. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04568-0 · Cited by 13
“Moreover, in poor prognosis, patients with sarcoma and neuroblastoma who also had unsuccessful chemotherapy have been shown to have high levels of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in their tumor cells [82].”
BackgroundChimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Yu, T., Jiang, W., Wang, Y., Zhou, Y. Y., Jiao, J., & Wu, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5628 · Cited by 14
“T cell therapy holds potential as a management option for high‑risk sarcomas (28,85).”
BackgroundImmunotherapeutic Strategies in the Management of Osteosarcoma
Supra, R., & Agrawal, D. K. (2023) · Journal of Orthopaedics and Sports Medicine · doi:10.26502/josm.511500076 · Cited by 12
“Additionally, CAR-T cells have been shown to inhibit Insulin-Like Growth Factor 1 (IGF-1) and receptor tyrosine and prolong the survival in OS mouse models [60].”
BackgroundSun, C., MA, X., ZHOU, C., Zhang, Z., & GUO, J. (2023) · Anticancer Research · doi:10.21873/anticanres.16514 · Cited by 10
Targeting the Tumor Microenvironment of Ewing Sarcoma
Morales, E., Olson, M., Cardenas, F. I., Luetkens, T., & Atanackovic, D. (2021) · Immunotherapy · doi:10.2217/imt-2020-0341 · Cited by 11
Alrifai, D., Sarker, D., & Maher, J. F. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1100204 · Cited by 10
Barzegari, A., Salemi, F., Kamyab, A., Aratikatla, A., Nejati, N., Valizade, M., Eltouny, E., & Ebrahimi, A. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100635 · Cited by 9
“The clinical success of CAR T cell treatments has been constrained by adverse events, such as on-target, off-tumor toxicity arising from the recognition of healthy tissue expressing the target antigen [44].”
InfluentialGad, A. Z., El‐Naggar, S., & Ahmed, N. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.07.004 · Cited by 8
Castillo, J. J. S., Llavata, L., Fort‐Culillas, R., Cobo, P. A., Moreno, R., Codony, C., del Muro, X. G., Alemany, R., Piulats, J. M., & Martín-Liberal, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311143 · Cited by 9
Exploring transposable elements: new horizons in cancer diagnostics and therapeutics
Chaaban, A., Sleem, R., Santina, J., Rima, M., & Ibrahim, J.-N. (2025) · Mobile DNA · doi:10.1186/s13100-025-00366-9 · Cited by 11
“…inter-leukin-13 (IL-13) cytokines in K562 (erythroleukemia), Daudi (B-cell Burkitt lymphoma), MCF-7 (breast cancer), DB (B-cell lymphoma), and EBV-LCL (EBV-transformed B lymphoblasts) cell lines compared to the RPMI8226 control B cells, offering a promising therapy for IGF1R positive cancers [270].”
InfluentialChew, H. Y., Chan, V., Simpson, F., & Dolcetti, R. (2020) · Cancers · doi:10.3390/cancers12113392 · Cited by 6
“Anti-IGF-1R CAR T cells and anti-ROR1 CAR T cells derived from healthy donors showed cytotoxicity against IGF-1R positive and ROR1 positive sarcoma cell lines in vitro, respectively, and were able to release IFN-γ, TNF-α and IL-13 upon antigen stimulation [82].”
BackgroundInfluentialHarnessing the immune responses: a new frontier in Ewing sarcoma treatment
Patel, D. S., Desai, R. T., Pandya, A. J., Kothari, N. R., Patel, R., & Chorawala, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02848-5 · Cited by 6
Appelbaum, J., Pinto, N. R., & Orentas, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00011-1 · Cited by 6
Ou, X., Gao, G., Ma, Q., Qin, D., Li, K., Feng, M., Gao, Y., Zeng, Y., Chen, Y., He, X., et al. (2025) · Angiogenesis · doi:10.1007/s10456-025-10008-6 · Cited by 7
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors
Esmaeilzadeh, A., Jafari, D., Elahi, R., Bazargan, M., Rafie, M. Z., & Mansourabadi, A. H. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_156 · Cited by 5
Zweers, T. J., Lommerse, J., van Maanen, E., & Chatterjee, M. S. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01429-5 · Cited by 3
“ROR1 is a cell surface protein that mediates signals from its ligand, the secreted glycoprotein Wnt5a [1–5].”
Caltavituro, A., Buonaiuto, R., Pietroluongo, E., Morra, R. P., Salomone, F., Placido, P. D., Pagliuca, M., Vaia, A., Ottaviano, M., Tortora, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030874 · Cited by 4
Overall review of curative impact and barriers of CAR-T cells in osteosarcoma
Li, G., Wang, H., & Meftahpour, V. (2024) · EXCLI journal · doi:10.17179/excli2023-6760 · Cited by 8
Goodspeed, A. E., Bodlak, A., Duffy, A. B., Nelson-Taylor, S., Oike, N., Porfilio, T. E., Shirai, R., Walker, D., Treece, A. L., Black, J. O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.18.576251 · Cited by 3
Immunotherapy in pediatric bone sarcomas: Current progress and future directions
Weil, R., & Loeb, D. M. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2690876 · Cited by 2
“32 In ES, tumor ‑ specific antigens proposed as targets include VEGFR2, IGF-1 R, ROR1, GD2, B7-H3 and EphA2.”
Self-citationRustagi, V., Nagar, G., Mittal, P., Singh, A. K., & Singh, I. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00018-1 · Cited by 3
Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets
Jiauddin, M., Reddy, K. P., Ravi, H., & Ramachandran, B. (2025) · American Journal of Translational Research · doi:10.62347/ymeu1808 · Cited by 2
“Several potential downstream targets of EWS-FLI1, such as insulin-like growth factor 1 receptor (IGF1R), poly (ADP-ribose) polymerase (PARP), and the Wnt/β-catenin signal - ing pathway, have been identified [48, 49].”
Immunotherapy for Resected Pulmonary Metastases
Morse, M. A. (2015) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2015.09.009 · Cited by 2
“A recent report suggested the possible utility of this approach.(59) The investigators generated IGF1R and ROR1 CAR-Ts based on observation of IGF1R and ROR1 expression in most Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma cell lines.”
BackgroundThe Role of CAR-T Cells in Targeting Cancer Stem Cells
Maali, A., & Sharifzadeh, Z. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_13 · Cited by 2
LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma
Blanchard, T., Faridi, P., Xu, C. B., Bear, A. S., Rasool, R. U., Huang, G., Lim, T., Ayala, R., Gabunia, K., Ji, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96877-9 · Cited by 3
Meligy, O. E., Elemam, N. M., Hassan, W. A., & Talaat, I. M. (2025) · Children · doi:10.3390/children12091249 · Cited by 2
“These CAR-T cells significantly slowed the growth of RMS tumors in vitro [126].”
Moonat, H., Huang, G., Dhupkar, P. M., Schadler, K., Gordon, N. B., & Kleinerman, E. S. (2017) · Cancer translational medicine · doi:10.4103/ctm.ctm_3_17 · Cited by 1
Diagnosis and Progress in Biological Treatment of Osteosarcoma
谢, 欣. (2019) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2019.93017 · Cited by 1
Immunotherapy for Pediatric Sarcomas
Pribnow, A. K., Straathof, K. C. M., & Majzner, R. G. (2020) · Pediatric oncology · doi:10.1007/978-3-030-51160-9_12 · Cited by 1
Estudo da expressão de microRNAs em amostras de carcinossarcomas e sarcomas uterinos
dos Anjos, L. G. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2017.tde-07032017-115512
“O estudo de Huang e colaboradores (2014), mostrou que esse gene (ROR1) foi altamente expresso em linhagens celulares de sarcoma, incluindo sarcoma de Ewing, osteossarcoma, rabdomiossarcoma embrionário ou alveolar e fibrossarcoma (Huang et al., 2015).”
BackgroundTashiro, H., Scherer, L. D., & Brenner, M. K. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm069.pub2
Metadata
- Authors
- Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., Rader, C., Hamby, C. V., Loeb, D. M., Cairo, M. S., & Zhou, X.
- Affiliations
- New York Medical College (US)
- University of Minnesota (US)
- Johns Hopkins University (US)
- Scripps Research Institute (US)
- Corresponding author
- Zhou, Xianzheng
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-14
- Volume
- 10
- Issue
- 7
- Pages
- e0133152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4501840
- OpenAlex
- W925209273
- Cited by
- 109
- References
- 54
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 10 · 2023: 16 · 2022: 10 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 3
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R21AI092220, AI092220)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- chimeric antigen receptor T cells, IGF-1 receptor, ROR1, sarcoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, fibrosarcoma, Sleeping Beauty transposon, adoptive T cell therapy, tumor xenograft models, cytokine production, high-risk sarcoma
- MeSH terms
- Animals, Bone Neoplasms, DNA Transposable Elements, Humans, Interferon-gamma, Receptors, Antigen, T-Cell, Sarcoma, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Interferon-alpha, Receptors, Somatomedin, Receptor, IGF Type 1, Interleukin-13, Adoptive Transfer, K562 Cells, Cell Line, Tumor, Mice, Receptor Tyrosine Kinase-like Orphan Receptors, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.